FDA Removes 12 Peptides from Category 2 (April 2026): What the Next Step Means

On 15 April 2026 the FDA published an updated version of its bulk drug substances list for Section 503A compounding. Effective 22 April 2026, seven days after publication, twelve peptides have been formally removed from Category 2. Among them are several of the most discussed research substances of recent years: BPC-157, TB-500, Epitalon, GHK-Cu, LL-37, MOTS-C, KPV, Semax, DSIP and Melanotan II.

At first glance this reads like the direct implementation of the RFK reclassification announcement from February 2026. In bureaucratic terms, it is exactly that: the formal FDA step. But and this is the crucial nuance: removal from Category 2 does not mean these peptides may be used in US compounding pharmacies starting tomorrow. Actual access depends on a further procedure the FDA has scheduled for July 2026.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Regulatory frameworks differ by jurisdiction. All peptides mentioned are sold for research purposes only. Always verify the legal status in your country before purchasing.

Timeline: How We Got Here

For researchers following the US regulatory process from a distance, it is easy to conflate the separate steps. The sequence:

2023–2024: The FDA moves 19 widely used research peptides into Category 2. Compounding pharmacies may no longer prepare them. Demand shifts to grey-market sources.
27 February 2026: HHS Secretary Robert F. Kennedy Jr. announces the reclassification of 14 peptides on the Joe Rogan Experience. A political statement of intent, not yet a formal FDA act.
15 April 2026: The FDA publishes the updated bulk drug substances list. Twelve peptides are removed from Category 2.
22 April 2026: The removal takes legal effect.
23–24 July 2026: The Pharmacy Compounding Advisory Committee (PCAC) holds hearings on seven of these substances. Only after these hearings and a final FDA determination can the peptides be added to the 503A bulks list.

The stops in between are not just weeks of paperwork, but a substantive scientific review process.

The Twelve Affected Peptides

The updated FDA list removes the following twelve substances from Category 2:

Peptide	Research Area
BPC-157	tissue repair, gastrointestinal regeneration
LL-37	antimicrobial peptide, immune modulation
DiHexa	cognitive research, hepatocyte growth factor mimetic
DSIP (Emideltide)	sleep regulation, neuroactive
Epitalon	telomere and longevity research
GHK-Cu (injectable)	skin regeneration, copper peptide
KPV	anti-inflammatory, gut health
PEG-MGF	muscle regeneration, IGF-1 variant
Melanotan II	melanocortin receptor, pigmentation
MOTS-C	mitochondrial peptide, metabolic
Semax	cognitive function, neuroprotection
TB-500	muscle and tissue repair

Readers of our earlier article on the 2026 FDA regulation will recognise the list: yes, this is essentially the implementation of the Kennedy announcement, though with a different count (12 rather than 14). Some peptides originally mentioned, such as Thymosin Alpha-1 or CJC-1295, do not appear in the April list.

Why "Removed from Category 2" Does Not Mean "Available for Compounding"

This is the most important nuance of the entire process, and it is routinely glossed over in lighter coverage. The FDA's 503A framework works on this principle:

Category 1 / 503A bulks list: Explicitly permitted for compounding.
Category 2: Explicitly excluded due to safety or efficacy concerns.
Category 3 / not listed: Under review or unclear status. A pharmacy may not automatically use the substance just because it is not in Category 2.

Removing a peptide from Category 2 clears the explicit prohibition. But it does not mean the substance has reached the 503A bulks list, which is what is actually required for compounding. In between lies the process of the Pharmacy Compounding Advisory Committee (PCAC), an FDA advisory panel that reviews each substance individually for scientific evidence, safety data, and clinical need. Only the final FDA vote after PCAC review determines whether a substance is added to the positive list.

For compounding pharmacies this means: from 22 April they can no longer classify the twelve peptides as "actively prohibited". Whether they may legally prepare them will only become clear after the PCAC review and the subsequent FDA decision. The industry sometimes refers to this as "regulatory limbo": no longer forbidden, but not yet cleared either.

PCAC Meetings on 23 and 24 July 2026

The FDA has already announced the agenda for the upcoming deliberations. Over two days, seven of the twelve removed peptides will be discussed scientifically:

Day 1, 23 July 2026

BPC-157
KPV
TB-500
MOTS-C

Day 2, 24 July 2026

DSIP (Emideltide)
Semax
Epitalon

The remaining five substances (LL-37, DiHexa, GHK-Cu injectable, PEG-MGF, Melanotan II) are not listed in this round. Whether they will be handled in later sessions or on a separate track has not been specified by the FDA. The Skin, Scar and Regenerative Medicine Institute (SSRP) was among the first professional bodies to publicly summarise the process and the agenda.

At PCAC hearings, FDA scientists, industry representatives and public comments present data on safety, clinical utility and suitability as a bulk substance. The committee then votes. The final decision rests with the FDA, which typically follows the vote but is not legally bound by it.

What This Means for EU Researchers

No direct legal change. The EU legal framework for research chemicals is not affected by this FDA step. Peptides marketed exclusively for research purposes remain outside the scope of medicines legislation, as long as no therapeutic claims are made. Researchers in the EU sourcing BPC-157, TB-500 or Epitalon for laboratory research do not need to align with US categorisation.

Three indirect market signals are nonetheless relevant:

Demand rotation. Once US compounding pharmacies may potentially resume production after PCAC review, part of US demand could shift from the international grey market back into the regulated channel. This can influence raw material price dynamics.
Quality pressure. Formal regulation brings formal scrutiny. Reputable vendors worldwide will need to deliver higher documentation standards to remain credible to international customers.
Signal effect. The FDA is sending a signal: peptides are not categorically "too risky for compounding" but individually assessable. In the longer term this may also shape the debate at the EMA and at national EU authorities.

What This Means for the US Compounding Landscape

For American compounding pharmacies and their patients, 22 April is a symbolic turning point, not an operational clearance. Realistic scenarios:

Cautious pharmacies will wait until after the PCAC review and the formal addition to the 503A bulks list before offering preparations. Legal risk: offering a non-listed substance can still lead to warning letters or enforcement action.
More aggressive vendors may argue that removal from Category 2 combined with the Kennedy announcement already provides sufficient regulatory cover. This position is legally contested.
Patients and prescribing physicians should expect a transition period of several months. Anyone asking today "when can I get BPC-157 from a compounding pharmacy again?" should expect the answer "earliest Q3/Q4 2026".
GLP-1 agonists are not affected by this easing. The two-track strategy we already described in the March article on 2026 FDA regulation remains in place.

Connection to PeptidesDirect

PeptidesDirect stocks a large share of the affected substances as research chemicals. Regardless of how the US situation develops, the legal basis in the EU is stable: sale for research use, clear labelling, certificates of analysis per batch.

Our product pages for the peptides named in the April removal:

For context on how the European market is positioned relative to the US shifts, see also Why EU-Based Peptide Vendors Are Growing in Importance in 2026 and Peptide Sciences Shut Down: What EU Researchers Need to Know.

Outlook: What to Watch Through Q3 2026

The coming months will determine whether the April removal leads to substantive clearance or remains stuck in bureaucratic limbo. Key dates and signals:

June 2026: The EMA guideline on the manufacture of synthetic peptides enters into force. More relevant for EU manufacturers than the FDA process.
23–24 July 2026: PCAC meetings. Voting results are public and will clearly indicate the FDA's further direction.
August–September 2026: First formal FDA determinations after PCAC votes are to be expected. Addition to the 503A bulks list would be the concrete release step.
Q4 2026: How many of the twelve peptides are actually available for compounding again by the end of the year depends on PCAC recommendations, public consultation and FDA publications.
The remaining five peptides without a July slot. Whether LL-37, DiHexa, GHK-Cu injectable, PEG-MGF and Melanotan II are negotiated separately remains open.
Cross-border and import controls. Greater clarity on the US side may lead to increased attention to import shipments, especially when directed to US private individuals. For research customers operating within the EU, nothing changes.

Summary

22 April 2026 is a formal milestone but not an end point. The FDA has removed twelve peptides from Category 2 and thereby bureaucratically implemented the political direction announced in February. Actual clearance for compounding pharmacies, however, depends on the July 2026 PCAC review and the subsequent FDA decisions.

For researchers in the EU, nothing changes at the regulatory level. The event is nonetheless indirectly relevant because it affects the global demand and quality landscape. The coming months will show whether a formal removal act turns into an actual return of these twelve substances to regulated channels, or whether the process stalls in bureaucratic limbo.

Affected Peptides at PeptidesDirect

Of the 12 peptides removed from Category 2, we carry the following nine as research material:

BPC-157 – regeneration, tissue and gut
TB-500 – muscle and tendon regeneration
Epitalon – telomere activity, longevity
GHK-Cu – copper peptide, skin and wound healing
LL-37 – antimicrobial peptide
KPV – anti-inflammatory, skin and gut
MOTS-C – mitochondrial signalling peptide
Semax – neuroprotection, cognitive function
Melanotan 2 – melanocortin receptor agonist

All products are sold exclusively for research purposes and meet EU requirements for purity and documentation.